Axsome Therapeutics, Inc. (AXSM) analyst actions
Rating and price-target actions on AXSM in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the AXSM overview →
7 measured AXSM analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation | Press release | -0.25% | -0.24% | |
| Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD) | Press release | -0.93% | +3.08% | |
| Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) | Press release | -0.30% | +0.75% | |
| Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms | Press release | -2.55% | -2.74% | |
| Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia | Press release | -0.73% | -1.62% | |
| Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder | Press release | -3.75% | -3.52% | |
| Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder | Press release | +2.19% | +5.08% |
Keep exploring
More AXSM: earnings → · SEC filings → · AXSM overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Rubius Therapeutics, Inc. (RUBY) | 392 | -0.32% | 45% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 391 | +0.13% | 52% |
| RA PHARMACEUTICALS (RARX) | 391 | -0.04% | 45% |
| Checkpoint Therapeutics, Inc. (CKPT) | 389 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.